DAS28-γGT for the prediction of major cardiovascular events in rheumatoid arthritis: results from the ESPOIR cohort
Main finding · MACEResult — go to the resultHazard ratio 3.11 95% CI 1.41–5.43Authors' conclusion
The DAS28-γGT was identified in this large prospective cohort as an independent predictor of MACE in patients with RA.
Study context
- Population
- RA patients of the ESPOIR cohort with baseline γGT activity and follow-up to at least 1 year (536 women; mean age 49 years)34 MACE recorded
- Participants
- 696 patients
- Exposure
- DAS28-γGT >9.4 vs lower DAS28-γGT
- Outcome
- Merit of the DAS28-γGT in predicting the occurrence of MACE
Methodological details13-year outcome, ROC curve analysis, multivariate Cox analyses
- 13-year outcome
- ROC curve analysis
- Multivariate Cox analyses
Main finding
MACE
Hazard ratio
3.11
95% CI 1.41–5.43
DAS28-γGT >9.4vs DAS28-γGT ≤9.4
HR 3.11 (95% CI 1.41–5.43)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Independent predictors of MACE (multivariate Cox analyses)
- Higher DAS28-γGT, HR
- 2.44 (95% CI 1.05, 5.64)
- Age, HR
- 1.04 (95% CI 1.01, 1.07)
- Diabetes mellitus, HR
- 4.12 (95% CI 1.55, 10.95)
Dose effect of DAS28-γGT for MACE-risk prediction
- Dose effect, in line with the application of the Framingham risk score
Original publication
DAS28-γGT for the prediction of major cardiovascular events in rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford). Published 31 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →